Table 1 Baseline characteristics of participants after exclusion of other autoimmune diseases

From: An observational and genetic investigation into the association between psoriasis and risk of malignancy

 

Non-PSO

PSO

SMD

 

N = 463136

N = 13463

Age (years)

56.9 (8.11)

57.4 (7.98)

0.057

Male (N, %)

212843 (46.0%)

6840 (50.8%)

0.097

BMI (kg/m2)

27.4 (4.76)

28.3 (5.09)

0.178

SBP (mmHg)

138 (18.50)

139 (18.20)

0.052

FBG (mmol/L)

5.12 (1.23)

5.20 (1.39)

0.064

Smoking status (%)

  

0.228

 Never

256841 (55.5%)

6001 (44.6%)

 Previous

158186 (34.2%)

5428 (40.3%)

 Current

48109 (10.4%)

2034 (15.1%)

Alcohol intake frequency (%)

  

0.048

 Daily or almost daily

94455 (20.4%)

2992 (22.2%)

 Three or four times a week

107973 (23.3%)

3086 (22.9%)

 Once or twice a week

120155 (25.9%)

3314 (24.6%)

 One to three times a month

51509 (11.1%)

1491 (11.1%)

 Special occasions only

52594 (11.4%)

1520 (11.3%)

 Never

36450 (7.9%)

1060 (7.9%)

Physical activity (%)

  

0.047

 Low intensity

86288 (18.6%)

2759 (20.5%)

 Moderate intensity

189459 (40.9%)

5420 (40.3%)

 High intensity

187389 (40.5%)

5284 (39.2%)

Medication use

 Glucocorticoids (N, %)

4780 (1.03%)

282 (2.09%)

<0.001

 Methotrexate (N, %)

305 (0.07%)

403 (2.99%)

<0.001

 Cyclosporine (N, %)

68 (0.01%)

15 (0.11%)

<0.001

  1. PSO psoriasis, BMI body mass index, SBP systolic blood pressure, FBG fasting blood glucose, SMD, standardized mean difference.
Back to article page